Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Rheumatology International
Published in: Rheumatology International 8/2015

01-08-2015 | Review Article - Genes and Disease

Correlation between P2X7 receptor gene polymorphisms and gout

Authors: Qiong-yao Gong, Yong Chen

Published in: Rheumatology International | Issue 8/2015

Login to get access

Abstract

Not all patients with hyperuricemia will develop acute gouty arthritis, indicating that other initiating factors need to be considered. The P2X7 receptor is an adenosine triphosphate-gated nonselective cation channel that has also been suggested to be a proinflammatory receptor. In the immune system, the P2X7 receptor is involved in the processing and release of various proinflammatory cytokines, including interleukin-1β (IL-1β), IL-18 and tumor necrosis factor-α (TNF-α). IL-1β is a central cytokine in the initiation of the acute inflammatory response, which plays a key role in the pathogenesis of gout and the pathology of acute gouty arthritis. This review will explore single-nucleotide polymorphisms in the P2X7R gene [including rs1718119 (Ala348Thr), rs208294 (His155Tyr), rs3751143 (Glu496Ala), rs28360457 (Arg307Gln) and rs2230911 (Thr357Ser)] and their correlation with the incidence of gout. We conclude that P2X7R gene polymorphisms impact the secretion of IL-1β and thus play a vital role in the pathogenesis of gout.
Literature
1.
Robinson PC, Horsburgh S (2014) Gout: joints and beyond, epidemiology, clinical features, treatment and co-morbidities. Maturitas 78(4):245–251PubMedCrossRef
2.
Tao JH, Zhang Y, Li XP (2013) P2X7R: a potential key regulator of acute gouty arthritis. Semin Arthritis Rheum 43(3):376–380PubMedCrossRef
3.
Ferrari D, Pizzirani C, Adinolfi E et al (2006) The P2X7 receptor: a key player in IL-1 processing and release. J Immunol 176(7):3877–3883PubMedCrossRef
4.
5.
Steiger S, Harper JL (2014) Mechanisms of spontaneous resolution of acute gouty inflammation. Curr Rheumatol Rep 16(1):392PubMedCrossRef
6.
7.
8.
9.
Pope RM, Tschopp J (2007) The role of interleukin-1 and the inflammasome in gout: implications for therapy. Arthritis Rheum 56(10):3183–3188PubMedCrossRef
10.
Martinon F (2010) Mechanisms of uric acid crystal-mediated autoinflammation. Immunol Rev 233(1):218–232PubMedCrossRef
11.
Terkeltaub RA, Schumacher HR, Carter JD et al (2013) Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator. Arthritis Res Ther 15(1):R25PubMedCentralPubMedCrossRef
12.
Schlesinger N, Alten RE, Bardin T et al (2012) Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 71(11):1839–1848PubMedCrossRef
13.
14.
15.
Rumney RM, Wang N, Agrawal A et al (2012) Purinergic signalling in bone. Front Endocrinol (Lausanne) 3:116
16.
Gever JR, Cockayne DA, Dillon MP et al (2006) Pharmacology of P2X channels. Pflugers Arch 452(5):513–527PubMedCrossRef
17.
Trautmann A (2009) Extracellular ATP in the immune system: more than just a “danger signal”. Sci Signal 2(56):pe6PubMedCrossRef
18.
Eleftheriadis T, Pissas G, Karioti A et al (2013) Uric acid induces caspase-1 activation, IL-1β secretion and P2X7 receptor dependent proliferation in primary human lymphocytes. Hippokratia 17(2):141–145PubMedCentralPubMed
19.
Alves LA, Bezerra RJ, Faria RX et al (2013) Physiological roles and potential therapeutic applications of the P2X7 receptor in inflammation and pain. Molecules 18(9):10953–10972PubMedCrossRef
20.
21.
Lenertz LY, Gavala ML, Zhu Y et al (2011) Transcriptional control mechanisms associated with the nucleotide receptor P2X7, a critical regulator of immunologic, osteogenic, and neurologic functions. Immunol Res 50(1):22–38PubMedCentralPubMedCrossRef
22.
Andrei C, Margiocco P, Poggi A et al (2004) Phospholipases C and A2 control lysosome-mediated IL-1 beta secretion: implications for inflammatory processes. Proc Natl Acad Sci USA 101(26):9745–9750PubMedCentralPubMedCrossRef
23.
Skaper SD (2011) Ion channels on microglia: therapeutic targets for neuroprotection. CNS Neurol Disord Drug Targets 10(1):44–56PubMedCrossRef
24.
Stokes L, Fuller SJ, Sluyter R et al (2010) Two haplotypes of the P2X(7) receptor containing the Ala-348 to Thr polymorphism exhibit a gain-of-function effect and enhanced interleukin-1beta secretion. FASEB J 24(8):2916–2927PubMedCrossRef
25.
Cabrini G, Falzoni S, Forchap SL et al (2005) A His-155 to Tyr polymorphism confers gain-of-function to the human P2X7 receptor of human leukemic lymphocytes. J Immunol 175(1):82–89PubMedCrossRef
26.
Gu BJ, Zhang W, Worthington RA et al (2001) A Glu-496 to Ala polymorphism leads to loss of function of the human P2X7 receptor. J Biol Chem 276(14):11135–11142PubMedCrossRef
27.
Wesselius A, Bours MJ, Arts IC et al (2012) The P2X(7) loss-of-function Glu496Ala polymorphism affects ex vivo cytokine release and protects against the cytotoxic effects of high ATP-levels. BMC Immunol 13:64PubMedCentralPubMedCrossRef
28.
Shemon AN, Sluyter R, Fernando SL et al (2006) A Thr357 to Ser polymorphism in homozygous and compound heterozygous subjects causes absent or reduced P2X7 function and impairs ATP-induced mycobacterial killing by macrophages. J Biol Chem 281(4):2079–2086PubMedCrossRef
29.
Gu BJ, Sluyter R, Skarratt KK et al (2004) An Arg307 to Gln polymorphism within the ATP-binding site causes loss of function of the human P2X7 receptor. J Biol Chem 279(30):31287–31295PubMedCrossRef
30.
Roger S, Mei ZZ, Baldwin JM et al (2010) Single nucleotide polymorphisms that were identified in affective mood disorders affect ATP-activated P2X7 receptor functions. J Psychiatr Res 44(6):347–355PubMedCrossRef
31.
Amaral FA, Costa VV, Tavares LD et al (2012) NLRP3 inflammasome-mediated neutrophil recruitment and hypernociception depend on leukotriene B(4) in a murine model of gout. Arthritis Rheum 64(2):474–484PubMedCrossRef
32.
Portales-Cervantes L, Niño-Moreno P, Doníz-Padilla L et al (2010) Expression and function of the P2X(7) purinergic receptor in patients with systemic lupus erythematosus and rheumatoid arthritis. Hum Immunol 71(8):818–825PubMedCrossRef
33.
Sorge RE, Trang T, Dorfman R et al (2012) Genetically determined P2X7 receptor pore formation regulates variability in chronic pain sensitivity. Nat Med 18(4):595–599PubMedCentralPubMedCrossRef
Metadata
Title
Correlation between P2X7 receptor gene polymorphisms and gout
Authors
Qiong-yao Gong
Yong Chen
Publication date
01-08-2015
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 8/2015
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-015-3258-5

Other articles of this Issue 8/2015

Rheumatology International 8/2015 Go to the issue

Short Communication - Food for Thought

Infrapatellar fat pad volume is greater in individuals with patellofemoral joint osteoarthritis and associated with pain

Original Article - Imaging

Ultrasonographic measurement of carotid artery resistive index and diastolic function of the heart in gout patients

Original Article - Observational Research

Investigation of subclinical atherosclerosis in psoriatic arthritis patients with minimal disease activity

Original Article - Genes and Disease

Hypermethylation of glucocorticoid receptor gene promoter results in glucocorticoid receptor gene low expression in peripheral blood mononuclear cells of patients with systemic lupus erythematosus

Letter to the Editor - Food for Thought

Meat consumption and gout: Friend, foe or neither?

Original Article - Genes and Disease

Polymorphisms in the glucocorticoid receptor gene and in the glucocorticoid-induced transcript 1 gene are associated with disease activity and response to glucocorticoid bridging therapy in rheumatoid arthritis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits